DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on January 28, 2008; DOI: 10.1124/dmd.107.019067


0090-9556/08/3604-759-768$20.00
DMD 36:759-768, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
dmd.107.019067v1
36/4/759    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yan, L.
Right arrow Articles by Hunt, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yan, L.
Right arrow Articles by Hunt, C. A.

Predictions of Hepatic Disposition Properties Using a Mechanistically Realistic, Physiologically Based ModelFormula

Li Yan, Shahab Sheihk-Bahaei, Sunwoo Park, Glen E. P. Ropella, and C. Anthony Hunt

The UCSF/UCB Joint Graduate Group in Bioengineering, University of California, Berkeley and San Francisco, California (L.Y., S.S.-B., C.A.H.); Department of Bioengineering and Therapeutic Sciences, the BioSystems Group, the University of California, San Francisco, California (S.P., G.E.P.R., C.A.H.); and Tempus Dictum, Inc., Eagle Creek, Oregon (G.E.P.R.)

Quantitative mappings were established between drug physicochemical properties (PCPs) and parameter values of a physiologically based, mechanistically realistic, in silico liver (ISL). The ISL plugs together autonomous software objects that represent hepatic components at different scales and levels of detail. Microarchitectural features are represented separately from the mechanisms that influence drug metabolism. The same ISL has been validated against liver perfusion data for sucrose and four cationic drugs: antipyrine, atenolol, labetalol, and diltiazem. Parameters sensitive to drug-specific PCPs were tuned so that ISL outflow profiles from a single ISL matched in situ perfused rat liver outflow profiles of all five compounds. Quantitative relationships were then established between the four sets of drug PCPs and the corresponding four sets of PCP-sensitive, ISL parameter values; those relationships were used to predict PCP-sensitive, ISL parameter values for prazosin and propranolol given only their PCPs. Relationships were established using three different methods: 1) a simple linear correlation method, 2) the fuzzy c-means algorithm, and 3) a simple artificial neural network. Each relationship was used separately to predict ISL parameter values for prazosin and propranolol, given their PCPs. Those values were applied in the ISL used earlier to predict the hepatic disposition details for each drug. Although we had only sparse data available, all predicted disposition profiles were judged reasonable (within a factor of 2 of referent profile data). The order of precision, based on a similarity measure, was 3 > 2 > 1.


Address correspondence to: Dr. C. Anthony Hunt, Department of Bioengineering and Therapeutic Sciences, University of California, 513 Parnassus Ave., S-926, San Francisco, CA 94143. E-mail: a.hunt{at}ucsf.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.